{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:31:02Z","timestamp":1761514262804,"version":"3.37.3"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T00:00:00Z","timestamp":1538438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T00:00:00Z","timestamp":1538438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1111\/ane.13023","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T13:20:17Z","timestamp":1535980817000},"page":"49-63","source":"Crossref","is-referenced-by-count":8,"title":["Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli"],"prefix":"10.1155","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-1670","authenticated-orcid":false,"given":"Martin","family":"Holtkamp","sequence":"first","affiliation":[{"name":"Department of Neurology, Epilepsy-Center Berlin-Brandenburg; Charit\u00e9 - Universit\u00e4tsmedizin Berlin; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Delanty","sequence":"additional","affiliation":[{"name":"Beaumont Hospital; Royal College of Surgeons in Ireland; Dublin Ireland"},{"name":"FutureNeuro Research Centre; Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Sales","sequence":"additional","affiliation":[{"name":"Centro Hospitalar e Universit\u00e1rio de Coimbra; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Serratosa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"McMurray","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd; Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico La Fe; Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,2]]},"reference":[{"key":"10.1111\/ane.13023-BIB0001|ane13023-cit-0001","unstructured":"BIAL - Portela & C\u00aa., SA Zebinix\u00ae Summary of Product Characteristics 2017 https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf"},{"key":"10.1111\/ane.13023-BIB0002|ane13023-cit-0002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/epi.13993","article-title":"Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study","volume":"59","author":"Trinka","year":"2018","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0003|ane13023-cit-0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0004|ane13023-cit-0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1111\/ane.13023-BIB0005|ane13023-cit-0005","unstructured":"Sunovion Pharmaceuticals Inc Aptiom \u00ae Prescribing Information 2017 https:\/\/www.aptiom.com\/Aptiom-Prescribing-Information.pdf"},{"key":"10.1111\/ane.13023-BIB0006|ane13023-cit-0006","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1528-1167.2008.01618_2.x","article-title":"Clinical relevance of patients with epilepsy included in clinical trials","volume":"49","author":"Tlusta","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0007|ane13023-cit-0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/epd.2010.0303","article-title":"The evolution of antiepileptic drug development and regulation","volume":"12","author":"Arzimanoglou","year":"2010","journal-title":"Epileptic Disord"},{"key":"10.1111\/ane.13023-BIB0008|ane13023-cit-0008","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s00415-017-8618-5","article-title":"Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures","volume":"264","author":"Villanueva","year":"2017","journal-title":"J Neurol"},{"key":"10.1111\/ane.13023-BIB0009|ane13023-cit-0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nrl.2013.02.013","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results","volume":"29","author":"Massot","year":"2014","journal-title":"Neurologia"},{"key":"10.1111\/ane.13023-BIB0010|ane13023-cit-0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eplepsyres.2015.06.013","article-title":"Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests","volume":"115","author":"Ley","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.13023-BIB0011|ane13023-cit-0011","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.eplepsyres.2014.06.017","article-title":"Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study","volume":"108","author":"Correia","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.13023-BIB0012|ane13023-cit-0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ane.12720","article-title":"EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure","volume":"136","author":"Villanueva","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13023-BIB0013|ane13023-cit-0013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.12574","article-title":"Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy","volume":"134","author":"Holtkamp","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13023-BIB0014|ane13023-cit-0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.12734","article-title":"Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study","volume":"136","author":"Chaves","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13023-BIB0015|ane13023-cit-0015","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.13023-BIB0016|ane13023-cit-0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10309-016-0055-4","article-title":"Daten zum aktuellen Praxiseinsatz von Eslicarbazepinacetat in Deutschland","volume":"29","author":"Holtkamp","year":"2016","journal-title":"Z Epileptol"},{"issue":"Suppl 2","key":"10.1111\/ane.13023-BIB0017|ane13023-cit-0017","first-page":"230","article-title":"The use of eslicarbazepine acetate in intellectual disability patients with epilepsy across 2 academic epilepsy centres in Dublin, 2009-2015","volume":"57","author":"Gunko","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1111\/ane.13023-BIB0018|ane13023-cit-0018","first-page":"52","article-title":"Preliminary data on the efficacy and tolerability of eslicarbazepine as adjunctive therapy in patients with refractory partial epilepsy","volume":"56","author":"Boero","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1111\/ane.13023-BIB0019|ane13023-cit-0019","first-page":"186","article-title":"The ROME study (Retrospective Observational Multicenter study on ESL): \u2018efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy for adult patients with partial onset seizures and global effect on quality of life\u2019","volume":"57","author":"Assenza","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1111\/ane.13023-BIB0020|ane13023-cit-0020","first-page":"190","article-title":"Transitioning patients from oxcarbazepine to eslicarbazepine acetate","volume":"57","author":"M\u00e4kinen","year":"2016","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0021|ane13023-cit-0021","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jns.2013.07.226","volume":"333","author":"Keogh","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.13023-BIB0022|ane13023-cit-0022","unstructured":"UCB Pharma SA Keppra\u00ae Summary of Product Characteristics 2018 https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000277\/WC500041334.pdf"},{"key":"10.1111\/ane.13023-BIB0023|ane13023-cit-0023","unstructured":"Janssen-Cilag Limited Topamax\u00ae Summary of Product Characteristics 2009 https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Topamax_30\/WC500018620.pdf"},{"key":"10.1111\/ane.13023-BIB0024|ane13023-cit-0024","unstructured":"Sanofi Epilim\u00ae Summary of Product Characteristics 2018 https:\/\/www.medicines.org.uk\/emc\/medicine\/6781"},{"key":"10.1111\/ane.13023-BIB0025|ane13023-cit-0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1684\/j.1950-6945.2003.tb00001.x","article-title":"Rational conversion from antiepileptic polytherapy to monotherapy","volume":"5","author":"Baulac","year":"2003","journal-title":"Epileptic Disord"},{"key":"10.1111\/ane.13023-BIB0026|ane13023-cit-0026","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs-rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1111\/ane.13023-BIB0027|ane13023-cit-0027","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0028|ane13023-cit-0028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yebeh.2017.02.028","article-title":"Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study","volume":"73","author":"Toledano","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.13023-BIB0029|ane13023-cit-0029","first-page":"131","article-title":"Long-term treatment with oxcarbazepine in clinical practice","volume":"20","author":"Passarella","year":"2005","journal-title":"Funct Neurol"},{"key":"10.1111\/ane.13023-BIB0030|ane13023-cit-0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.seizure.2005.12.008","article-title":"Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice","volume":"15","author":"Pauletto","year":"2006","journal-title":"Seizure"},{"key":"10.1111\/ane.13023-BIB0031|ane13023-cit-0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ane.12920","article-title":"Lacosamide monotherapy in clinical practice: A retrospective chart review","volume":"138","author":"Villanueva","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13023-BIB0032|ane13023-cit-0032","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13023-BIB0033|ane13023-cit-0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eplepsyres.2018.03.006","article-title":"Real world experience with lacosamide monotherapy- a single center 1-year follow-up study","volume":"142","author":"Maloney","year":"2018","journal-title":"Epilepsy Res"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.13023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.13023\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T22:09:45Z","timestamp":1720562985000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.13023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.13023","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"type":"print","value":"0001-6314"}],"subject":[],"published":{"date-parts":[[2018,10,2]]}}}